Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2758 companies scored · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2758 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.41% Alpha · 90D
Long–short spread +5.19% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 278 ▼ 463 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

296 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
151 REPLReplimune Group, Inc. Life Sciences 0.35 $1.0B Unlock rating and forecasts
152 MNKDMANNKIND CORP Life Sciences 0.62 $977M Unlock rating and forecasts
153 IMTXImmatics N.V. Life Sciences 0.35 $902M Unlock rating and forecasts
154 MGTXMeiraGTx Holdings plc Life Sciences 0.31 $891M Neutral -0.27% -0.53% ·
155 QDELQuidelOrtho Corp Life Sciences 0.06 $885M Neutral -0.42% -0.92% ▲ 1
156 ANROAlto Neuroscience, Inc. Life Sciences 0.22 $861M Unlock rating and forecasts
157 RIGLRIGEL PHARMACEUTICALS INC Life Sciences 0.05 $859M Neutral -0.06% -0.08% ·
158 CYRXCryoport, Inc. Life Sciences 0.29 $853M Neutral -0.09% -0.14% ·
159 ABUSArbutus Biopharma Corp Life Sciences 0.03 $835M Unlock rating and forecasts
160 CGEMCullinan Therapeutics, Inc. Life Sciences 0.40 $832M Unlock rating and forecasts
161 GLUEMonte Rosa Therapeutics, Inc. Life Sciences 0.15 $831M Unlock rating and forecasts
162 AVBPArriVent BioPharma, Inc. Life Sciences 0.19 $821M Unlock rating and forecasts
163 ALMSALUMIS INC. Life Sciences 0.28 $792M Unlock rating and forecasts
164 VSTMVerastem, Inc. Life Sciences 0.31 $783M Unlock rating and forecasts
165 HELPHelus Pharma Inc. Life Sciences 0.18 $771M Unlock rating and forecasts
166 ARDXARDELYX, INC. Life Sciences 0.39 $770M Neutral -0.21% -0.39% ·
167 COLLCOLLEGIUM PHARMACEUTICAL, INC Life Sciences 0.63 $755M Neutral -0.41% -0.91% ▲ 1
168 GERNGERON CORP Life Sciences 0.11 $752M Unlock rating and forecasts
169 IVAInventiva S.A. Life Sciences 0.25 $709M Unlock rating and forecasts
170 DNAGinkgo Bioworks Holdings, Inc. Life Sciences 0.30 $692M Unlock rating and forecasts
171 SANASana Biotechnology, Inc. Life Sciences 0.26 $680M Unlock rating and forecasts
172 LXRXLEXICON PHARMACEUTICALS, INC. Life Sciences 0.44 $676M Unlock rating and forecasts
173 FDMT4D Molecular Therapeutics, Inc. Life Sciences 0.21 $670M Unlock rating and forecasts
174 IMMXImmix Biopharma, Inc. Life Sciences 0.31 $662M Unlock rating and forecasts
175 ACHVACHIEVE LIFE SCIENCES, INC. Life Sciences 0.41 $657M Unlock rating and forecasts
176 ANNXAnnexon, Inc. Life Sciences 0.29 $646M Unlock rating and forecasts
177 DSGNDesign Therapeutics, Inc. Life Sciences 0.24 $645M Unlock rating and forecasts
178 GYREGYRE THERAPEUTICS, INC. Life Sciences 0.05 $645M Unlock rating and forecasts
179 AURAAura Biosciences, Inc. Life Sciences 0.42 $633M Unlock rating and forecasts
180 PRMEPrime Medicine, Inc. Life Sciences 0.21 $629M Unlock rating and forecasts
181 CADLCandel Therapeutics, Inc. Life Sciences 0.42 $627M Unlock rating and forecasts
182 WVEWave Life Sciences, Inc. Life Sciences 0.18 $617M Unlock rating and forecasts
183 AVTXAvalo Therapeutics, Inc. Life Sciences 0.26 $604M Unlock rating and forecasts
184 SLDBSolid Biosciences Inc. Life Sciences 0.13 $593M Unlock rating and forecasts
185 IRWDIRONWOOD PHARMACEUTICALS INC Life Sciences 0.22 $578M Neutral -0.10% -0.17% ▲ 1
186 OLMAOlema Pharmaceuticals, Inc. Life Sciences 0.25 $576M Unlock rating and forecasts
187 SGMTSagimet Biosciences Inc. Life Sciences 0.27 $569M Unlock rating and forecasts
188 CRMDCorMedix Inc. Life Sciences 0.18 $566M Neutral -0.34% -0.71% ·
189 CLYMClimb Bio, Inc. Life Sciences 0.46 $564M Unlock rating and forecasts
190 PHATPhathom Pharmaceuticals, Inc. Life Sciences 0.16 $560M Unlock rating and forecasts
191 STTKShattuck Labs, Inc. Life Sciences 0.30 $544M Unlock rating and forecasts
192 DBVTDBV Technologies S.A. Life Sciences 0.35 $536M Neutral -0.34% -0.70% ·
193 SLNSilence Therapeutics plc Life Sciences 0.13 $522M Unlock rating and forecasts
194 DRUGBRIGHT MINDS BIOSCIENCES INC. Life Sciences 0.22 $512M Unlock rating and forecasts
195 PBYIPUMA BIOTECHNOLOGY, INC. Life Sciences 0.01 $507M Unlock rating and forecasts
196 CBIOGYRE THERAPEUTICS, INC. Life Sciences 0.12 $507M Unlock rating and forecasts
197 CTMXCytomX Therapeutics, Inc. Life Sciences 0.05 $497M Unlock rating and forecasts
198 FTHFaeth Therapeutics, Inc. Life Sciences 0.07 $486M Neutral -0.13% -0.23% ·
199 ACRSAclaris Therapeutics, Inc. Life Sciences 0.37 $483M Unlock rating and forecasts
200 EOLSEvolus, Inc. Life Sciences 0.49 $469M Unlock rating and forecasts
151–200 of 296 Previous Next
Since the previous run

Rating changes

▲ 278▼ 463
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.